Linked Life Data

9396196

Source:http://linkedlifedata.com/resource/pubmed/id/9396196

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1997-12-17
pubmed:abstractText
I-123-N-(2-Diethylaminoethyl) 4-lodobenzamide (I-123IDAB) has recently been introduced as a radiopharmaceutical agent in the management of patients with malignant melanoma. We tested the diagnostic potential of this substance in 5 patients suspected of having an ocular malignant melanoma. I-123-IDAB scintigraphy identified 4 patients with high tracer uptake in the pathologic eye. Three cases were confirmed histologic as a malignant melanoma, the fourth patient was submitted to radiotherapy. The amelanotic (histologically confirmed) irismelanoma of the fifth patient could not be detected. From these preliminary results we conclude that I-123-IDAB scintigraphy may be a valuable tool for establishing the diagnosis of malignant melanotic melanoma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0081-0746
pubmed:author
pubmed:issnType
Print
pubmed:volume
263
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
109-13
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
I-123-IDAB: a new tracer for scintigraphic visualisation of malignant melanoma.
pubmed:affiliation
Department of Ophthalmology, Free University of Brussels.
pubmed:publicationType
Journal Article